INTRODUCTION
Chordoma is a very rare bone sarcoma originating from the skull base or the spine. 1 Even after optimal treatment of the primary tumor, most patients with chordoma have local and/or metastatic recurrences that cannot be cured. 1, 2 Conventional chordoma is unresponsive to cytotoxic chemotherapy. In recent years, molecular therapies (including imatinib, sorafenib, and EGFR inhibitors) have been introduced but have had limited impact on disease outcome. [1] [2] [3] In 2010, we reported the results of the molecular analysis of tumor samples from 22 naive chordomas showing an involvement of the mammalian target of rapamycin (mTOR) pathway in most patients. 4 Afterward, we explored the antitumor effect of imatinib plus sirolimus in 10 chordoma patients with secondary resistance to imatinib, observing 1 and 6 partial responses (PRs) by RECIST and Choi criteria, respectively. 5 Given these preliminary results, we evaluated within a phase 2 trial (EUDRACT number: 2010-021755-34) the activity of imatinib plus everolimus (IE) in patients with advanced chordoma. When tumor tissue was available, we
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PATIENTS AND METHODS
We conducted an Italian, single-arm, investigatorinitiated, phase 2 clinical study in adults with progressive advanced chordoma, defined as locally advanced and unresectable (both primary and recurrent) or metastatic cases. Pathology, PDGFRB, S6, and/or 4EBP1 status were centrally determined. The primary inclusion criteria were pathologic diagnosis of chordoma, advanced disease, centrally confirmed evidence of progression by Choi in the 6 months before entering the study, and Eastern Cooperative Oncology Group performance status ≤2. Between January 2011 and March 2015, 45 patients were enrolled, 43 started the experimental treatment (2 screening failures) and 40 were evaluable for response according to Choi criteria.
The study was conducted at the Fondazione IRCCS Istituto Nazionale Tumori in Milan, Italy. The institutional review board approved the study. All patients provided written informed consent.
Supplementary Figure 1 shows the CONSORT recruitment flowchart.
PDGFRB, S6, and 4EBP1 Assessment
PDGFRB status was assessed by immunohistochemistry and/or by western blot analysis depending on the type/quantity of available tumor tissue. 5 Immunohistochemistry was evaluated in cases with tumor tissue fixed in formalin and not decalcified. Further details regarding immunohistochemistry assessment are available in the Supporting Information.
The percentage of phosphorylated cells was calculated on the total amount of neoplastic cells and was evaluated as follows: low (>5%-20%), moderate (>20%-60%), and high (≥60%) of immunodecorated cells.
Treatment
Patients received 400 mg/day imatinib and 2.5 mg/ day everolimus continuously until progression/toxicity. Everolimus and imatinib plasma levels were dosed on days 1, 8, 15, and 28; then at 8 and 12 weeks; then every 3 months; and during the "end of study" visit. Additional samples for pharmacokinetics were taken in case of grade (G) ≥2 nonhematologic toxicity and G≥3 hematologic toxicity. Everolimus plasma levels had to be kept within the range of 10 to 20 ng/mL, and the daily dose of everolimus was adjusted accordingly (ie, decreased to 2.5 mg every other day, or increased to 5 mg/day).
Treatment was withheld for G≥3 hematologic toxicity and G≥2 nonhematologic toxicity, and it was resumed after recovery to G≤2 hematologic toxicity or G≤1 nonhematologic toxicity.
Patients had a regular physical examination and a complete blood count/serum chemistry evaluation. All patients were evaluated at baseline with whole body computed tomography (CT) and magnetic resonance imaging (MRI) and/or CT of the tumor sites. Adverse events (AE) were graded according to the US National Cancer Institute Common Toxicity Criteria (version 4.03).
Efficacy and Safety Evaluation
Intent-to-treat (ITT) and safety populations included all enrolled patients who received at least 1 dose of IE (n = 43). Per-protocol (PP) analyses were performed in patients who were evaluable for response by Choi (n = 40) or RECIST (n = 42) criteria, depending on the endpoint considered.
Response Assessment
Response was assessed by way of CT and/or MRI after 4 weeks, then every 2 months, according to Choi and RECIST 1.1 criteria. (Additional details regarding Choi response assessment are available in the Supporting Information.) A centralized review of all the scans by a sarcoma expert radiologist was performed.
Study Design and Statistical Analysis
Descriptive statistics and frequency tabulation were used to summarize patient and tumor characteristics.
The primary endpoint was overall response rate (ORR) according to Choi criteria. 6, 7 We applied the Choi criteria as defined for gastrointestinal stromal tumor (GIST) and extended them to MRI, 7 because the RECIST criteria were already found to be inadequate to detect a response in chordoma treated with targeted therapy. 1, 8 The trial was designed as a single-arm phase 2 study with a fixed sample size of 40 patients. With this number, the trial was powered to detect a relative risk of ≥80% and to exclude a relative risk of ≤60%, with alpha and beta error levels being fixed at 10%. Secondary endpoints were ORR according to RECIST 1.1 criteria, overall survival (OS), progression-free survival (PFS) according to Choi and RECIST criteria, and clinical benefit rate according to Choi criteria. ORR was defined as the proportion of patients who achieved complete response (CR) or PR, whereas clinical benefit rate was considered the proportion of patients who achieved CR or PR or stable disease for at least 6 months. The corresponding 95% confidence intervals (CIs) were calculated based on the binomial distribution.
Cancer October 15, 2018 PFS and OS curves were estimated using the Kaplan-Meier method and compared using log-rank tests. Times to event occurrence were computed from the start of treatment to the date when the event was recorded, or censored at the date of last follow-up assessment in event-free patients. Analyses were performed considering 2-sided P < .05 as statistically significant and using SAS version 9.4 (SAS Institute, Cary, NC) or R software version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria). Table 1 summarizes the patient characteristics. Thirteen (30.2%) patients were pretreated with imatinib, 7 of whom had progression and 5 of whom had stable disease (this information was not available for 1 patient).
RESULTS
At 
Antitumor Activity
Forty of 43 patients who entered the study were evaluable for response according to Choi criteria (the MRI images were not available for 3 patients), and 42 patients were evaluable according to RECIST criteria (there was an early interruption for 1 patient).
The best Choi criteria responses were PR in 9 (20.9%) patients, stable disease in 24 (55.8%) patients, and progressive disease in 7 (16.3%) patients; 3 (7%) patients were not evaluable. Figure 1 shows a Choi criteria PR. The Choi criteria ORR was 20.9% (95% CI, 10%-36%) in the ITT population; the corresponding estimate according to the PP approach was 22.5% (95% CI, 10.8%-38.5%). PR was observed in 6 of 30 cases of naive chordoma and in 3 of 13 patients who were pretreated with imatinib. All patients pretreated with imatinib who responded to IE had stable disease while under imatinib monotherapy; no patient who progressed as a best response to imatinib monotherapy benefited from EI.
The best RECIST responses were PR (n = 1 [2.3%]), stable disease (n = 37 [86.0%]), and progressive disease (n = 4 [9.3%]); 1 (2.3%) patient was not evaluable. The RECIST ORR was 2.3% (95% CI, 0.1%-12.3%) in the ITT analysis and 2.4% (95% CI, 0.1%-12.6%) in the PP analysis.
Supporting Figure 2 shows the waterfall plots of the best changes in tumor diameter, density, and signal intensity.
The clinical benefit rate according to Choi criteria (ITT analysis) was 76.7% (n = 33; 95%-CI, 61.4%-88.2%). All values are presented as n (%) unless indicated otherwise. a Progression, n = 7; stable disease, n = 5; response not known, n = 1.
Cancer October 15, 2018 The median PFS according to Choi criteria was 11.5 months (IQR, 4.6-17.6 months), with a 9-, 12-, and 24-month PFS rate of 58.8% (95% CI, 45.5%-76.0%), 48.1% (95% CI, 34.8%-66.5%), and 21% (95% CI, 11.3%-39.2%), respectively ( Fig. 2A) . The median PFS for patients who were responsive according to Choi criteria was 20.5 months (IQR, 11.2-38.7 months), whereas the PFS for patients without evidence of response was 7.3 months (IQR, 3.6-15.2 months) (P = .1327). In the PP analysis, the corresponding estimates were 20.5 months 
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Cancer October 15, 2018 (IQR, 11.2-38.7 months) and 7.0 months (IQR, 2.8-14.0 months, respectively (P = .0395) (Fig. 2B) . Nine of 13 (69.2%) patients pretreated with imatinib achieved a PFS of ≥6 months according to Choi criteria, whereas 11 (84.6%) patients achieved a PFS of ≥6 months according to RECIST. The median PFS according to RECIST was 14 months (IQR, 10.3-50 months), with a 9-, 12-, and 24-month PFS rate of 80.2% (IQR, 68.8%-93.5%), 63.6% (IQR, 50%-81%), and 38% (IQR, 25%-57.8%), respectively. The median OS was 47.1 (IQR 17.8-54.8) months (Fig. 3A) . The median OS was 50 months (IQR, 44.5-54.87 months) for patients who were responsive according to Choi criteria and 47.1 months (IQR, 15.9-55 months) for patients without evidence of response (P = .5955). In the PP population, the corresponding estimates were 50 months (IQR, 44.5-54.8 months) and 34.3 months (IQR, 15.9-47.5 months), respectively, P = .3559 (Fig. 3B) . Table 2 summarizes the results of the study. PDGFRB expression was evaluated in 35 cases (positive, n = 26; negative, n = 9). 4EBP1 expression was evaluated and found to be positive in 29 cases, 24 of which were phosphorylated. The phosphorylation value was high, moderate, low, and not evaluable in 6, 11, 5, and 2 cases, respectively (Supporting Fig. 3 ). S6 expression was evaluated in 22 cases and was found to be expressed in all cases and phosphorylated in 19 cases. The phosphorylation value was high, moderate, low, and not evaluable in 5, 12, 0, and 2 cases, respectively (Supporting Fig.  3 ). 4EBP1 and/or S6 exhibited a high phosphorylation score in all evaluable and responsive patients (n = 5), while it was low or moderate in all evaluable patients who had a Choi progressive disease as a best response (Table 2) .
PDGFRB, S6, 4EBP1 Assessment

Drug Delivery and Toxicity
Thirty-nine patients started their treatment with imatinib 400 mg/day and everolimus 2.5 mg mg/day. In 4 cases, the treatment was precautionally initiated with imatinib monotherapy and everolimus was added at 4 weeks. The dose of everolimus was permanently reduced to 2.5 mg every other day in 7 patients (16.3%), while a daily dose increase was never required.
Toxicity caused a temporary treatment discontinuation in 26 (60.5%) patients and a definitive treatment interruption in 13 (30.2%) patients. Thirty-one (72.1%) patients experienced G≥2 AEs (G2, n = 21; G3, n = 10). The most frequent G≥2 AEs (ie, occurring in ≥10% of patients) and all ≥G3 AEs are listed in Table 3 . An everolimus blood level of >20 ng/mL was detected in 3 of 10 patients with G3 AE. 
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DISCUSSION
In this investigator-initiated phase 2 study, 43 patients with progressive advanced chordoma received IE. Forty patients were evaluable for response according to Choi criteria, and 42 patients were evaluable according to RECIST. The Choi ORR (ie, the primary study endpoint) was 21% (PR, n = 9), whereas only 1 (2%) patient achieved a RECIST PR. The median PFS was 11.5 and 14 months according to Choi and RECIST, respectively. A trend toward better PFS and OS, albeit not significant, was observed in patients who responded according to Choi criteria (median PFS, 20.5 months; median OS, 50 months) compared with those who did not (median PFS, 7 months; median OS, 34 months). In evaluable cases, the percentage of tumor cells that showed the mTOR effectors' activation correlated with the response. Toxicity led to the definitive interruption of IE in 30.2% cases. This study has limitations related to the challenges of conducting a clinical study of a rare disease. The study population was small and variable in terms of clinical presentation and prior treatments. Chiefly, IE achieved a low ORR, as was observed with imatinib as monotherapy, 8 and was formally negative (its planned target was a Choi ORR >60%), which does not support As discussed in Patients and Methods, the phosphorylation (p) extent of 4E-BP1 and of S6 was graded as low, moderate, or high corresponding to 5%-20%, >20%-60%, or ≥60% phosphorylated cells, respectively.
Cancer October 15, 2018 IE as front-line treatment in advanced chordoma. The selection of the target was based on the results of a retrospective study on imatinib plus sirolimus in chordoma with secondary resistance to imatinib, in which we observed a Choi PR in 7 of 10 cases. 8 In contrast to that study, in the present study we included naive patients and patients who had been pretreated with imatinib which may have affected the results.
Nevertheless, 21% of patients entering this study showed a Choi response, including 3 of 13 patients who were refractory to imatinib. This suggests that in chordoma, the addition of an mTOR inhibitor to imatinib can result in a resistance to imatinib in some patients. Notably, all responses in patients pretreated with imatinib were seen in those patients who showed an initial disease stabilization while receiving imatinib monotherapy. Undertaking a study limited to patients who previously had at least a tumor growth arrest for some period on imatinib would be a future hypothesis to derive from this trial.
With all the limitation related to its reproducibility, we selected Choi ORR as the primary endpoint for this study based on the experience that tumor responses to imatinib and target agents in chordoma can be nondimensional. 1, 5 Thus, although tumor response assessment based on Choi criteria is still to validate in chordoma and pending the definition of new response criteria in the disease, we preferred Choi to RECIST as response criteria. Notably, a radiologist with expertise in sarcoma reviewed all of the scans at the end of the study.
We observed a median PFS of almost 1 year (11.5 months). Of course, median PFS has to be interpreted with caution in the absence of a control arm. However, we allowed only patients with evidence of progression in the 6 months before entering the study. With all the limitations of comparisons between different studies, IE achieved a longer disease control than observed with other molecular agents investigated so far in chordoma (imatinib, 9-month median PFS; lapatinib, 6-month median PFS; sorafenib, 73% 9-month PFR vs 80.2% for IE). 5, 9, 10 Furthermore, although a selection bias cannot be ruled out in an uncontrolled study, a trend toward better PFS and OS was found in patients who responded according to Choi criteria compared with those who did not.
Molecular data support the activity of mTOR inhibitors in chordoma. 4, 11 In fact, mTOR pathway activation was confirmed in most patients included in this study. In a small number of cases, mTOR effectors appeared to be highly phosphorylated (ie, activation in ≥60% of tumor cells) in responsive patients, whereas they were phosphorylated to a low or moderate level in patients who did not respond. These findings suggest that the activation of the mTOR pathway is a potential predictor of response to IE. Data in the literature also show that everolimus may allow a time-dependent recruitment of 4EBP1 activation [12] [13] [14] and that the resulting incomplete proliferative arrest (of the 4EBP1/4E checkpoint) can be compensated by agents such as imatinib, which ablates the PI3K/AKT pathway, [15] [16] [17] thus supporting a combined approach. Of course, our observations should be confirmed in a larger series, evaluating pair-frozen and formalin-fixed, paraffin-embedded (FFPE) samples obtained from the tumor before starting IE. However, this type of study is challenging in a rare disease when patients are not amenable to surgical resection and in a tumor in which biopsy is a procedure with a known risk of tumor seeding.
1,2 For this last reason, a pretreatment biopsy and serial specimens to collect fresh material for translational research was not a mandatory procedure in our study.
In this trial, toxicity was not negligible, with 13 of 43 patients definitively interrupting their treatment because of an AE. Of course, this may have affected the overall results of the study. The large variability in pharmacokinetics of oral mTOR inhibitors is known, as well as the relationship between treatment drug exposure and treatment outcome and toxicity. 18 Unfortunately, toxicity was a common event despite our attempts to tailor the dose of everolimus on the plasma level.
In conclusion, our data do not support IE as a frontline treatment for chordoma. However, they highlight that a subgroup of patients progressing on imatinib after response may benefit from the addition of everolimus to imatinib, reacquiring a Choi response or a tumor growth arrest. Thus, a possible treatment strategy to evaluate prospectively in chordoma patients who progress on imatinib after an initial benefit and have evidence of a high level of 
